BRYHALI

Peak

halobetasol propionate

NDATOPICALLOTION
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1

Mechanism of Action

signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.

Indications (1)

Clinical Trials (1)

NCT04720105Phase 4Completed

Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis

Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis

Loss of Exclusivity

LOE Date
Nov 2, 2031
68 months away
Patent Expiry
Nov 2, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
10478502
Nov 2, 2031
Product
U-2625
11839656
Nov 2, 2031
U-2625
11957753
Nov 2, 2031
Product
11986527
Nov 2, 2031
U-2625
12076403
Nov 2, 2031
Product